
|Videos|July 26, 2014
The Development of the HER2-Specific Inhibitor ONT-380 for Breast Cancer
Author(s)Robert L. Kirkman, MD
Robert L. Kirkman, MD, President and CEO, Oncothyreon, discusses the development of ONT-380, an oral HER2-specific inhibitor, for the treatment of patients with HER2-positive metastatic breast cancer.
Advertisement
Clinical Pearls
Robert L. Kirkman, MD, President and CEO, Oncothyreon, discusses the development of ONT-380, an oral HER2-specific inhibitor, for the treatment of patients with HER2-positive metastatic breast cancer.
- ONT-380 is being evaluated for the treatment of HER2-positive breast cancer in combination with T-DM1 and in combination with capecitabine and trastuzumab.
- This agent is well tolerated. EGFR-related side effects have not been observed.
- In a highly-pretreated population of patients with HER2-positive breast cancer, ONT-380 elicited a clinical benefit rate of 27%.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5








































